Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1649 1675 1797
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19358181 | METHODS OF TREATING TUMORS | Non-Final OA | Halozyme, Inc. |
| 17779499 | COMBINATION THERAPY FOR HEAD AND NECK CANCER | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18637337 | COMPOSITIONS AND METHODS OF TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | Final Rejection | Avidity Biosciences, Inc. |
| 17774125 | METHODS FOR TREATING LEUKEMIA | Non-Final OA | AMGEN INC. |
| 18026746 | METHODS OF TREATING AN INDIVIDUAL THAT HAS FAILED AN ANTI-PD-1/ANTI-PD-L1 THERAPY | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 17477435 | METHODS FOR TREATING MULTIPLE MYELOMA | Final Rejection | Janssen Pharmaceutica NV |
| 17622634 | MODULATION OF DENDRITIC CELL FUNCTION BY THE PHOSPHOLIPID MESSENGER LPA | Non-Final OA | Cornell University |
| 17262667 | COMPOSITIONS AND METHODS FOR COMBATING MULTIDRUG-RESISTANT BACTERIA | Non-Final OA | University of Virginia Patent Foundation |
| 17776556 | Combination Therapy Based on PD-1 Signaling Inhibitors | Final Rejection | Kyoto University |
| 18266443 | COMPOSITIONS AND USES OF CD19 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED IMMUNE CELLS | Non-Final OA | City of Hope |
| 17041783 | SUBCUTANEOUS DOSING OF ANTI-CD38 ANTIBODIES | Non-Final OA | TAKEDA PHARMACEUTICAL COMPANY LIMITED |
| 18278394 | INTERCELLULAR ADHESION MOLECULE 1 (ICAM1) ANTIBODY DRUG CONJUGATE AND USES THEREOF | Non-Final OA | Children's Medical Center Corporation |
| 16624422 | CAPTURE OF CIRCULATING TUMOR CELLS USING CARBON NANOTUBE SPONGES | Final Rejection | UNIVERSITY OF DELAWARE |
| 17999735 | ADAPTER MOLECULES TO RE-DIRECT CAR T CELLS TO AN ANTIGEN OF INTEREST | Non-Final OA | UNIVERSITY OF ZURICH |
| 18299453 | COMPOSITION AND METHODS OF TREATMENT USING SYNERGISTICALLY-ENHANCED SUPPLEMENTATION | Non-Final OA | Xygenyx Inc. |
| 18037342 | METHODS FOR TREATING OR PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME | Final Rejection | CSL INNOVATION PTY LTD |
| 18185848 | ANTI-CD73 ANTIBODIES AND COMPOSITIONS | Non-Final OA | LES LABORATOIRES SERVIER |
| 17910310 | APPLICATION OF IFN-y IN PREPARING ANTI-TUMOR ADJUVANT DRUG | Non-Final OA | West China Hospital of Sichuan University |
| 18016964 | USE OF INHALED INTERFERON-BETA TO IMPROVE OUTCOME IN SARS-CoV-2 INFECTED PATIENTS | Final Rejection | SYNAIRGEN RESEARCH LIMITED |
| 17996878 | ANTI-CD73-ANTI-PD-1 BISPECIFIC ANTIBODY AND USE THEREOF | Non-Final OA | Akeso Biopharma, Inc |
| 17929417 | NATURAL KILLER CELLS | Non-Final OA | NK:IO Ltd |
| 17409589 | METHODS OF TREATING CANCER | Non-Final OA | CITIUS PHARMACEUTICALS, INC. |
| 17413468 | BARN DUST EXTRACT FOR THE PREVENTION AND TREATMENT OF DISEASES | Final Rejection | The Arizona Board of Regents on Behalf of the University of Arizona |
| 17334590 | METHODS OF TREATING IgA NEPHROPATHY WITH AN APRIL BINDING ANTIBODY | Non-Final OA | ADURO BIOTECH HOLDINGS, EUROPE B.V. |
| 17291340 | METHODS OF TREATING GRAVES' OPHTHALMOPATHY USING ANTI-FCRN ANTIBODIES | Non-Final OA | IMMUNOVANT SCIENCES GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy